Instil Bio/TIL

$10.60

-1.4%
-
1D1W1MYTD1YMAX

About Instil Bio

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.

Ticker

TIL

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Bronson Crouch

Employees

49

Headquarters

Dallas, United States

Instil Bio Metrics

BasicAdvanced
$69.66M
Market cap
-
P/E ratio
-$24.00
EPS
-
Beta
-
Dividend rate
$69.66M
$14.00
$6.07
18.77K
15.225
36.057
36.057
-38.65%
-52.96%
-40.84%
0.308
0.308
6.99%

What the Analysts think about Instil Bio

Analyst Ratings

Majority rating from 3 analysts.
Buy

Price Targets

Average projection from 3 analysts.
161.04% upside
High $54.00
Low $11.00
$10.60
Current price
$27.67
Average price target

Instil Bio Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-12.9M
-80.86%
Profit margin
0%
-

Instil Bio Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 30.05%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$8.80
-$2.80
-$10.40
-$1.99
-
Expected
-$3.10
-$3.27
-$2.00
-$2.85
-$2.23
Surprise
183.87%
-14.29%
420%
-30.05%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Instil Bio stock?

Instil Bio (TIL) has a market cap of $69.66M as of April 25, 2024.

What is the P/E ratio for Instil Bio stock?

The price to earnings (P/E) ratio for Instil Bio (TIL) stock is 0 as of April 25, 2024.

Does Instil Bio stock pay dividends?

No, Instil Bio (TIL) stock does not pay dividends to its shareholders as of April 25, 2024.

When is the next Instil Bio dividend payment date?

Instil Bio (TIL) stock does not pay dividends to its shareholders.

What is the beta indicator for Instil Bio?

Instil Bio (TIL) does not currently have a Beta indicator.

What is the Instil Bio stock price target?

The target price for Instil Bio (TIL) stock is $27.67, which is 158.36% above the current price of $10.71. This is an average based on projections from 3 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Instil Bio stock

Buy or sell Instil Bio stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing